Let’s dig into the relative performance of ICU Medical (NASDAQ: ICUI) and its peers as we unravel the now-completed Q2 medical devices & supplies - cardiology, neurology, vascular earnings season.

The medical devices and supplies industry, particularly in the fields of cardiology, neurology, and vascular care, benefits from a business model that balances innovation with relatively predictable revenue streams. These companies focus on developing life-saving devices such as stents, pacemakers, neurostimulation implants, and vascular access tools, which address critical and often chronic conditions. The recurring need for these devices, coupled with growing global demand for advanced treatments, provides stability and opportunities for long-term growth. However, the industry faces hurdles such as high research and development costs, rigorous regulatory approval processes, and reliance on reimbursement from healthcare systems, which can exert downward pressure on pricing. Looking ahead, the industry is positioned to benefit from tailwinds such as aging populations (which tend to have higher rates of disease) and technological advancements like minimally invasive procedures and connected devices that improve patient monitoring and outcomes. Innovations in robotic-assisted surgery and AI-driven diagnostics are also expected to accelerate adoption and expand treatment capabilities. However, potential headwinds include pricing pressures stemming from value-based care models and continued complexity changing from navigating regulatory frameworks that may prioritize further lowering healthcare costs.

The 4 medical devices & supplies - cardiology, neurology, vascular stocks we track reported a strong Q2. As a group, revenues beat analysts’ consensus estimates by 2.6%.

Thankfully, share prices of the companies have been resilient as they are up 6.6% on average since the latest earnings results.

ICU Medical (NASDAQ: ICUI)

Founded in 1984 and named for its initial focus on intensive care units, ICU Medical (NASDAQ: ICUI) develops and manufactures medical products for infusion therapy, vascular access, and vital care applications used in hospitals and other healthcare settings.

ICU Medical reported revenues of $547.9 million, flat year on year. This print exceeded analysts’ expectations by 2.8%. Overall, it was an exceptional quarter for the company with an impressive beat of analysts’ full-year EPS guidance estimates and a beat of analysts’ EPS estimates.

Vivek Jain, ICU Medical’s Chief Executive Officer, said, “Second quarter results were ahead of our expectations for Infusion Systems and generally in line with expectations for the remainder of the business."

ICU Medical delivered the slowest revenue growth of the whole group. Interestingly, the stock is up 9.9% since reporting and currently trades at $182.84.

Is now the time to buy ICU Medical? Access our full analysis of the earnings results here, it’s free.

Best Q2: Merit Medical Systems (NASDAQ: MMSI)

Founded in 1987 and now offering over 1,700 patented products across global markets, Merit Medical Systems (NASDAQ: MMSI) manufactures and markets specialized medical devices used in minimally invasive procedures for cardiology, radiology, oncology, critical care, and endoscopy.

Merit Medical Systems reported revenues of $418.8 million, up 9.5% year on year, outperforming analysts’ expectations by 3.3%. The business had an exceptional quarter with an impressive beat of analysts’ organic revenue estimates and an impressive beat of analysts’ full-year EPS guidance estimates.

Merit Medical Systems achieved the highest full-year guidance raise among its peers. The market seems happy with the results as the stock is up 8.9% since reporting. It currently trades at $90.79.

Is now the time to buy Merit Medical Systems? Access our full analysis of the earnings results here, it’s free.

Weakest Q2: Penumbra (NYSE: PEN)

Founded in 2004 to address challenging medical conditions with significant unmet needs, Penumbra (NYSE: PEN) develops and manufactures innovative medical devices for treating vascular diseases and providing immersive healthcare rehabilitation solutions.

Penumbra reported revenues of $390 million, up 14.9% year on year, in line with analysts’ expectations. It was a softer quarter as it posted a significant miss of analysts’ EPS estimates.

Penumbra delivered the fastest revenue growth but had the weakest performance against analyst estimates in the group. Interestingly, the stock is up 1.7% since the results and currently trades at $325.29.

Read our full analysis of Penumbra’s results here.

Artivion (NYSE: AORT)

Formerly known as CryoLife until its 2022 rebranding, Artivion (NYSE: AORT) develops and manufactures medical devices and preserves human tissues used in cardiac and vascular surgical procedures for patients with aortic disease.

Artivion reported revenues of $125.8 million, up 11.3% year on year. This result surpassed analysts’ expectations by 4.4%. Overall, it was a very strong quarter as it also produced a beat of analysts’ EPS estimates and full-year EBITDA guidance slightly topping analysts’ expectations.

Artivion scored the biggest analyst estimate beat but had the weakest full-year guidance update in the group. The stock is up 5.7% since reporting and currently trades at $28.08.

Read our full, actionable report on Artivion here, it’s free.

Market Update

Over the past year, investors have been forced to repeatedly answer the same question: what is the market’s biggest risk? The answer has changed several times, and each shift has reshaped market leadership.

Late in 2025 and early 2026, artificial intelligence became the market’s primary uncertainty. Investors questioned whether AI would erode software pricing power and weaken competitive moats as AI made it easier to replicate once-differentiated products.

By the spring, technology took a back seat to geopolitics. The U.S. conflict with Iran briefly became the market’s dominant narrative, raising concerns about oil prices, inflation, and global growth. But as energy markets remained orderly and fears of a prolonged supply disruption faded, investors quickly turned their focus back to fundamentals.

Want to invest in winners with rock-solid fundamentals? Check out our Hidden Gem Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.